Home » Stocks » PHAT

Phathom Pharmaceuticals, Inc. (PHAT)

Stock Price: $31.84 USD -0.11 (-0.34%)
Updated Aug 3, 2021 2:10 PM EDT - Market open
Market Cap 1.01B
Revenue (ttm) n/a
Net Income (ttm) -143.77M
Shares Out 31.33M
EPS (ttm) -4.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $31.84
Previous Close $31.95
Change ($) -0.11
Change (%) -0.34%
Day's Open 32.04
Day's Range 31.15 - 32.74
Day's Volume 32,496
52-Week Range 30.47 - 50.78

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

FLORHAM PARK, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatme...

2 months ago - GlobeNewsWire

FLORHAM PARK, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatme...

2 months ago - GlobeNewsWire

FLORHAM PARK, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatme...

2 months ago - GlobeNewsWire

FLORHAM PARK, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat...

3 months ago - GlobeNewsWire

FLORHAM PARK, N.J., April 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat...

3 months ago - GlobeNewsWire

FLORHAM PARK, N.J., March 30, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat...

4 months ago - GlobeNewsWire

Mustang Bio (NASDAQ: MBIO) shares are trading higher after the company announced the FDA has lifted the clinical hold for its pivotal phase 2 MB-107 clinical trial. The company plans to enroll the first...

Other stocks mentioned: MBIO, BNGO, IMVT
6 months ago - Benzinga

FLORHAM PARK, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

6 months ago - GlobeNewsWire

MENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and M...

Other stocks mentioned: PASG
6 months ago - Business Wire

FLORHAM PARK, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

7 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

7 months ago - GlobeNewsWire

Management and Key Opinion Leaders to discuss NERD and the vonoprazan NERD development program during virtual Investor Day webcast today at 1:00 PM (ET) Management and Key Opinion Leaders to discuss NER...

7 months ago - GlobeNewsWire

Phathom Pharmaceuticals (PHAT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

7 months ago - Zacks Investment Research

Topline results expected in second half of 2021 Topline results expected in second half of 2021

8 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

8 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

8 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatm...

8 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel tre...

10 months ago - GlobeNewsWire

FLORHAM PARK, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel trea...

11 months ago - GlobeNewsWire

FLORHAM PARK, N.J., July 13, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel trea...

1 year ago - GlobeNewsWire

First New Patients Randomized in PHALCON-EE and PHALCON-HP Trials Since Temporary Pause Announced in March First New Patients Randomized in PHALCON-EE and PHALCON-HP Trials Since Temporary Pause Announc...

1 year ago - GlobeNewsWire

FLORHAM PARK, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treat...

1 year ago - GlobeNewsWire

Phathom Pharmaceuticals: A Clinical-Stage Company With A De-Risked Pipeline For 2020

1 year ago - Seeking Alpha

About PHAT

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection... [Read more...]

Industry
Biotechnology
IPO Date
Oct 25, 2019
Stock Exchange
NASDAQ
Ticker Symbol
PHAT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for PHAT stock is "Buy." The 12-month stock price forecast is 58.17, which is an increase of 82.69% from the latest price.

Price Target
$58.17
(82.69% upside)
Analyst Consensus: Buy